Treatment with the investigational therapy encaleret normalized calcium levels for most people with chronic hypoparathyroidism in a small proof-of-principle study. That’s according to data announced by Bridgebio Pharma, which is developing encaleret with its affiliate Calcilytix Therapeutics. The company said it hopes to launch a clinical trial…
People with long-lasting hypoparathyroidism after thyroid surgery are at risk of having deteriorating kidney function, according to a study from Spain. “This study demonstrated that patients were at greater risk of chronic kidney disease, progression to end-stage kidney disease, and faster decline in [kidney function] compared to subjects without…
A Phase 2 clinical trial testing MBX 2109 in people with chronic hypoparathyroidism has finished enrolling participants, according to MBX Biosciences, the treatment’s developer and sponsor of the trial. “Completion of enrollment in our Phase 2 trial in [hypoparathyroidism] marks a significant milestone for MBX and brings us closer…
Long-lasting hypoparathyroidism following surgery is associated with more hospitalizations and higher healthcare-related medical costs compared with temporary hypoparathyroidism after surgery, a new U.S. study shows. The higher medical costs linked to such chronic disease were found to create a greater economic burden for patients, according to researchers. For one…
Even with conventional treatment, health complications including the formation of calcium deposits in the brain, cataracts in the eyes, and kidney stones are frequent among people with chronic hypoparathyroidism, especially those who’ve been living with the condition for a long time, according to an analysis of patients at a…
The U.S. Food and Drug Administration (FDA) has given fast track designation to eneboparatide, an experimental treatment for hypoparathyroidism that’s being investigated in a global Phase 3 clinical trial. This designation is intended to speed the development of therapies with the potential to address major unmet needs for serious…
Yorvipath (palopegteriparatide), a treatment for hypoparathyroidism previously known as TransCon PTH, now is available to patients in Germany and Austria, according to the therapy’s developer, Ascendis Pharma. The announcement comes about two months after the European Commission approved Yorvipath to treat adults with chronic hypoparathyroidism. Yorvipath,…
The European Commission has approved palopegteriparatide, also known as TransCon PTH, to treat adults with chronic hypoparathyroidism. Ascendis Pharma, the therapy’s developer, will market it in the European Union under the brand name Yorvipath, and expects the therapy’s commercial launch to begin in Germany next month. An…
The experimental therapy TransCon PTH was effective at controlling hypoparathyroidism caused by neck surgery for most patients in the PaTHway clinical trial, according to data presented at the American Thyroid Association (ATA) annual meeting by its developer Ascendis Pharma. “We are pleased to share with thyroid surgeons…
Hypoparathyroidism may play a role in serious health complications that require hospitalization for people with the disorder, but is rarely the direct cause of such problems, an Austrian study shows. Findings indicate the most common causes of serious health issues among people with chronic (ongoing) hypoparathyroidism are related to…
Get regular updates to your inbox.
